


[Home](#) > [News](#)

Marshall Wace LLP Purchases **Ecopetrol** S.A. (NYSE:EC) Shares

by Elaine Mendonça — March 12, 2023 in News



0 SHARES / 7 VIEWS

Share on Facebook

Share on Twitter

G+

↻

Marshall Wace LLP increased the number of **Ecopetrol** S.A. (NYSE: E.C.) shares that it owned by 120.8% during the third quarter, as stated in the most recent Form 13F filing that the firm made with the Securities and Exchange Commission (SEC).

At the end of the given time frame, the corporation had 1,249,618 shares in the oil and gas company.

During that period, the organization purchased an additional 683,746 shares of stock.

Marshall Wace LLP had approximately 0.06% of **Ecopetrol**'s stock as of the end of the most recent quarter, with a value of \$11,160,000.

It wasn't until recently that several industry veterans offered their perspectives on E.C. stock.

In a research report released on Friday, February 10th, HSBC lowered their price target for **Ecopetrol** from \$12.50 to \$12.00 and downgraded the company from a "buy" rating to a "hold" rating. HSBC also downgraded **Ecopetrol** to a "hold" rating.

The "buy" recommendation placed on shares of **Ecopetrol** by UBS Group has been changed to a "neutral" rating, and the price target established for the stock is \$13.00.

The findings of a study were made available to the general public on February 9th.

This past Friday, December 9th, a research report made public by StockNews.com shifted their recommendation for **Ecopetrol** from "buy" to "hold." The report was originally given as a "buy" recommendation.

The Goldman Sachs Group raised their price objective on **Ecopetrol** shares from \$10.30 to \$12.40 and upgraded the stock from a "neutral" rating to an "overweight" rating in a research

\$12.40 and upgraded the stock from a neutral rating to an overweight rating in a research report released on Friday, January 27th.

This was the final and most significant of the upgrades to be completed. Four of the most prominent professionals working in the equity research industry have given their recommendation to keep holding the stock.

According to Bloomberg, most financial analysts currently have the stock rated as "Hold," and the average price objective they have set for the stock is \$12.47.

The holdings of E.C.

By several institutional investors and hedge funds have been subject to recent alterations by several of these entities.

The Northern Trust Corporation made a 0.5 percent purchase of additional **Ecopetrol** stock during the first three months of 2018.

After making an additional purchase of 1,044 shares during the quarter, Northern Trust Corp. now has 198,961 shares of the oil and gas company's stock, currently valued at \$3,700,000.

This is because the company has 198,961 shares of the oil and gas company's stock. UBS Group AG increased the proportion of **Ecopetrol** stock owned by 11.1% during the first three months of 2018.

As a result of the purchase of an additional 1,058 shares during the quarter, UBS Group AG is now the owner of 10,610 shares of the oil and gas business.

The current market price of these shares is \$197, making the total value of these shares equal to that amount.

During the second quarter, Credit Suisse AG completed a 10.8% increase in the proportion of **Ecopetrol** stock it owned.

After making an additional purchase of 1,105 shares during the most recent period, Credit Suisse AG now owns 11,308 shares of the oil and gas company's stock, which is now valued at \$123,000.

This brings Credit Suisse AG's total ownership of the company's stock to \$123,000. Quantamental Technologies LLC increased the percentage of **Ecopetrol** shares that it held by 8.9% during the second quarter of the fiscal year. Quantamental Technologies LLC now holds 13,975 shares of the oil and gas company's stock, which is estimated at \$152,000 after making an additional purchase of 1,143 shares during the quarter.

And finally, during the second quarter, Amundi increased the proportion of **Ecopetrol** stock owned by one-hundredth percent.

After making additional purchases totaling 1,166 shares throughout the month, Amundi now has 115,698 shares of the oil and gas company in its portfolio.

The value of all of Amundi's holdings in the company comes to a total of 1,102,000 dollars. Currently, hedge funds and other institutional investors hold a combined total of 1.30 percent of the company's shares.

The opening price for shares traded on the NYSE: E.C. on Friday was \$11.01.

During the previous year, the price of **Ecopetrol** S.A. ranged from its all-time low of \$8.59 to its all-time high of \$19.81.

The current P/E ratio for the company is 2.89, and it has a beta value of 1.41.

The market capitalization of the company is \$22.63 billion.

The value of the debt-to-equity ratio comes in at 0.78, the quick ratio comes in at 1.15, and the current ratio comes in at 1.36.

The company's moving average over the previous 200 days is \$10.31, and the moving average over the previous 50 days is \$11.07.

In addition to producing crude oil and natural gas, **Ecopetrol** S.A.

Is involved in various research and development activities.

Its operations can be divided into petrochemicals and refining, logistics and transportation, and production and exploration.

The third category is logistics and transportation.

The Exploration and Production section is in charge of all activities associated with exploring new oil and gas reserves and producing these resources.

Tags: EC, Analyst Rating



Elaine Mendonça


Over the last nine years, Elaine has managed investment portfolio using fundamental analysis and value investing, emphasizing long-term time horizons.



Home > News

Barrington Research has issued earnings estimates for Anika Therapeutics, Inc. for the first quarter of 2023. (NASDAQ:ANIK)

by Roberto Liccardo — March 12, 2023 in News



0 SHARES / 5 VIEWS

Share on Facebook

Share on Twitter

NASDAQ: ANIK was first available for trading on Friday with a starting price of \$26.91.

Anika Therapeutics hit a low point over the past year of operations of \$19.95 per share, while the stock reached a 52-week high of \$32.51 per share.

The business's market capitalization is reportedly at \$393.16 million at the moment, while its P/E ratio stands at -26.13, and its beta value is 0.86.

The moving average price of the stock over the past fifty days is currently \$30.53, and the moving average price over the past two hundred days is \$28.06.

In a research note published on Tuesday, March 7, Barrington Research lowered its projections for Anika Therapeutics' earnings per share (EPS) for the first quarter of 2023.

The company Anika Therapeutics, INC is the one that came up with the projections for their client, Anika Therapeutics.

M.

Petusky, an analyst at Barrington Research, predicts that the biotechnology company will now earn \$0.29 per share for the quarter.

This represents a decrease from their earlier earnings of \$0.18 per share, which were reported earlier.

According to the recommendation made by Barrington Research, investors should "market perform" the stock.

The current consensus profit forecast for the full fiscal year of Anika Therapeutics is \$0.25 per share.

Anika Therapeutics will earn \$0.25 per share in the second quarter of 2023, \$0.21 per share in the third quarter, \$0.15 per share in the fourth quarter, \$9.00 per share in the fiscal year 2023, \$0.61 per share in the fiscal year 2024, according to another prediction made by Barrington Research.

Consequently, the proportions of the stock that institutional investors and hedge funds own have been rebalanced.

During the third quarter, Mutual of America Capital Management LLC achieved an 18.9% increase in the amount of Anika Therapeutics stock it owned, thanks to its successful investment strategies.

Mutual of America Capital Management LLC now has 2,905 shares of the stock held by the biotechnology business.

This is the result of purchasing an additional 462 shares during the period.

It is currently believed that these shares have a value of approximately \$69,000.

During the third quarter of 2018, Tower Research Capital LLC (TRC) increased the amount of Anika Therapeutics stock owned by 61.2% to bring its total ownership percentage to 100%.

Tower Research Capital LLC (TRC) increased its holdings in the stock of the biotechnology business by purchasing an additional 608 shares during the most recent quarter.

This brought its total holdings to 1,601 shares of the company's stock with a value of \$38,000, bringing its total holdings to 1,601 shares of the company's stock.

That company's holdings reflected a 4.7% increase in the proportion of Anika Therapeutics stock that Victory Capital Management INC owned as of the second quarter. Following the

acquisition of an additional 622 shares of the biotechnology company's stock during the most recent quarter. Victory Capital Management INC now holds 13,866 shares of the company's stock, which can be purchased for a total of \$309,000.

During the period covered by this report, Diker Management LLC brought its total holdings in Anika Therapeutics up to a 2.9% ownership level (the third quarter).

Diker Management LLC increased its holdings in the biotechnology company's stock by purchasing an additional 623 shares during the most recent quarter.

This brings their total purchase to 22,458 shares, valued at \$535,000.00.

During the fourth and final quarter of 2018, JPMorgan Chase & Co increased the amount of Anika Therapeutics stock owned by 6.2%.

The financial services provider, JPMorgan Chase & Co, has taken ownership of 11,264 shares in the biotechnology company.

The aggregate value of these shares is equal to \$334,000, and during the most recent quarter, JPMorgan Chase & Co bought an additional 658 shares of the company's stock.

Institutional investors currently own 91.57% of the company's total outstanding shares.

Anika Therapeutics, INC is a company that specializes in the research and development of therapeutic solutions for the treatment of wounds, the regeneration of damaged tissue, and the management of pain.

These therapeutic solutions are produced by the company and marketed to customers.

Its products are based on hyaluronic acid, which is a chemical polymer that can be found in nature and is also found naturally within the human body. Hyaluronic acid can be found in both of these places.

Tags: ANIK, Analyst Rating



Roberto Liccardo

Financial and marketing expert at Entrepreneur.com, covering finance, sales and marketing strategies. Proudly wearing 15 years of direct and managerial experience in intensive Digital Marketing and Financial Analytics.




Home > News

Marshall Wace LLP owns \$11.04 million of Biohaven Ltd. (NYSE:BHVN)

by Ronald Kaufman — March 12, 2023 in News





0 SHARES 13 VIEWS

[Share on Facebook](#)

[Share on Twitter](#)

[G+](#)



The most recent statement that Marshall Wace LLP submitted to the Securities and Exchange Commission revealed that during the third quarter, the company's holdings in Biohaven Ltd (NYSE: BHVN) were reduced by 32.2%.

After making a transaction during the period that resulted in the sale of 621,868 shares of the company's stock, the institutional investor now has a total holding in the company that amounts to 1,306,756 shares.

Marshall Wace LLP owned 1.92% of Biohaven, which had a market value of \$11,044,000 as of the most recent report filed with the SEC.

After conducting recent research on the company, several professionals specializing in equity research have recently provided their opinions on the stock.

The day that SVB Securities started covering Biohaven shares was Tuesday, January 24, and they commemorated the occasion by publishing a research note on that date.

The rating that was given to the company was "Outperform," and the price target was set at 24 dollars. SVB Leerink reaffirmed an "outperform" rating on shares of Biohaven and set a target price of \$24.00 for the company's stock in a research note published on Tuesday, January 24.

The research note was about the company's stock. On Friday, December 2, BTIG Research published the first research report it would issue covering BioHaven shares.

The report was entitled "Biohaven Research Update." They suggested purchasing the stock at a price denoted as "buy" and established a price objective of \$24.00.

Last but not least, on January 4, JPMorgan Chase & Co announced in a research note that it would begin covering shares of Biohaven.

This marked the beginning of the company's coverage of Biohaven shares.

They rated the stock as "overweight" and decided that a price target of \$23.00 was appropriate.

There are a total of six analysts who have provided the company with a buy recommendation, while there are only three analysts who have provided it with a hold recommendation.

The company has been given an average recommendation of "Moderate Buy," The consensus price target has been set at \$48.75, as indicated by the data provided by Bloomberg.

Several institutional investors and other hedge funds recently altered the proportion of the company's stock they owned in response to recent market events. UBS Oconnor LLC spent approximately 572,000,000 dollars during the third quarter to increase its ownership stake in Biohaven.

Armistice Capital LLC made a new investment in Biohaven during the third quarter by

purchasing a position for \$9,022,000.

The transaction took place.

Throughout the second quarter, Pentwater Capital Management LP increased the number of shares it held in Biohaven, bringing the total value of its holdings in the company to \$208,365,000.

During the second quarter, Soros Fund Management LLC paid 182,866,600 to acquire an additional investment in Biohaven.

Last but not least, during the second quarter, TIG Advisors LLC completed the purchase of a new investment in Biohaven with a total value of \$150,062,000.

At present, hedge funds and various other types of institutional investors own 98.01 percent of the company's common stock.

When trading started on Friday, the price of a share of BHVN stock was \$13.52 per share. \$16.57 is the company's moving average price over the past 50 days, and \$44.37 is its average price over the past 200 days.

The business's market capitalization is reported to be \$921.52 million at the moment, while its P/E ratio is 0.97 and its beta is 1.12.

In the past year, the price of a share of Biohaven Ltd has fluctuated between \$5.54 and \$20.57, reaching a low of \$5.54 and a high of \$20.57, respectively.

Biohaven Ltd is a clinical-stage biopharmaceutical company established in the United States.

The company's mission is to discover and develop medicines for patients who suffer from debilitating neurological and neuropsychiatric diseases.

Troriluzole is a tripeptide prodrug undergoing clinical testing in Phase 3 to treat neurological and neuropsychiatric conditions.

BHV-5500 is a glutamate N-methyl-D-aspartate receptor antagonist with low-trapping properties to treat neuropathic pain.

The company is also working on the development of other pharmaceuticals. Verdiperstat is a type of enzyme inhibitor known as an irreversible myeloperoxidase inhibitor.

It is utilized in the treatment of neurodegenerative diseases.

Tags: BHVN, Analyst Rating



Ronald Kaufman

Ronald Kaufman is a veteran analyst and researcher with an expertise in the fields of Pharma, Cyber, FoodTech and Blockchain. He has been published on entrepreneur.com, GuruFocus, Finextra Research and others. He is currently a researcher at the Future Markets Research Tank (FMRT), where he does deep-dive market analysis and research in a number of industries.



B. Riley Research analysts lower Great Ajax Corp. earnings estimates (NYSE:AJX)

by Yasmin Mendonça — March 12, 2023 in News



0 SHARES / 5 VIEWS

[Share on Facebook](#)

[Share on Twitter](#)

[G+](#)



TheStreet lowered their rating on Great Ajax shares, moving them from a “C-” rating to a “D” in a report published on Friday, November 25th.

The rating change was announced. Four research analysts have given the stock a buy rating, while one has recommended that investors maintain their holdings.

According to Bloomberg, the company receives a recommendation of “Moderate Buy” on average, and the price of \$13.00 is projected to be the point at which it will reach a consensus among investors.

AJX began trading at \$7.15 on Friday.

The company has a price-to-earnings ratio of -5.67, a beta value of 1.80, and a market capitalization of \$165.38 million.

The simple moving average of the company’s stock price over the past two years is \$8.40; over the last fifty days, it has averaged \$8.23.

The cost of one bottle of Great Ajax can range anywhere from \$7.02 to \$11.78 over an entire year.

The debt-to-equity ratio stands at 1.89, the quick ratio at 1.89, and the current ratio at 1.86.

(NYSE: AJX) The Chief Executive Officer of Ajax Corporation, B. Riley, lowered his forecast for the amount of money that Great Ajax would earn during the first three months of 2023 in a research note made public on March 7th.

M. Howlett, an analyst at B. Riley, forecasts that the real estate investment trust will earn \$0.08 per share for the quarter.

This represents a significant decrease from the previous earnings of \$0.24 per share, which were reported by the real estate investment trust.

B. Riley has provided the company with a “buy” rating and has established a price objective of \$12.00 for it at present. Great Ajax should finish the year with earnings of \$0.87 per share if the projections made by investors are accurate.

This conclusion was reached after analyzing the recent performance of the company. Great Ajax was projected to earn \$0.15 per share in the second quarter of 2023, and B. Riley anticipated that the company would earn \$0.62 per share for the entire year.

Recently, several hedge funds have altered the interests they currently hold in the company due to recent transactions. Virtu Finance LLC made a fresh investment in the amount of \$80,000 in Great Ajax over the course of the final three months of the year 2018.

During the last three months of 2018, Susquehanna International Group LLP increased the percentage of ownership it held in Great Ajax by 339.9%. Susquehanna International Group LLP now has a total of 51,624 shares of the real estate investment trust with a market valuation of \$374,000 after acquiring an additional 39,888 shares during the most recent quarter.

This brings the company's total number of shares to 51,624.

During the last three months of 2018, Wells Fargo & Company MN increased the total number of Great Ajax shares by 194.1 percent. Wells Fargo & Company MN now has a total of 4,856 shares of the stock of the real estate investment trust, which have a combined value of \$35,000 thanks to the acquisition of an additional 3,205 shares during the preceding quarter.

The fourth quarter of 2018 saw Barclays PLC increase its stake in Great Ajax by 72.5 percent compared to the previous quarter.

Barclays PLC now owns 12,389 shares of the real estate investment trust, which are currently valued at \$89,000 after the company purchased an additional 5,206 shares during the most recent quarter.

And finally, during the final three months of the year, Geode Capital Management LLC completed a 2.0% increase in the number of Great Ajax shares included in its portfolio.

As a result of the recent purchase of 3,917 additional shares during the most recent fiscal quarter, Geode Capital Management LLC now owns a total of 199,260 shares of the real estate investment trust.

The current market value of these shares is \$1,444,000.

Institutional investors own approximately 74.63% of the total shares outstanding in the company.

As was mentioned earlier, on Tuesday, December 13th, Mary B.

Doyle, Chief Financial Officer of the company, sold 3,612 shares of company stock.

It was determined that each share was sold at an average price of \$7.56, which led to a total sale volume of 27,306.72 dollars.

The price at which the shares were sold was determined.

The chief financial officer now owns 95,759 business shares, which have a total value of \$723,938.04 as a result of the sale's success. When you click this link, you will be taken to a document given to the SEC.

This document contains information about the transaction and the presentation given to the SEC.

The company's current management and employees collectively own 6% of the company's shares.



Yasmim Mendonça

Yasmine's focus is on uncovering early-stage ideas with the potential to have a lasting impact. Her educational background includes a bachelor's degree in finance, an MBA, and two tests completed - the CFA and CMT.



Home > News

KeyCorp expects Agiliti, Inc. (NYSE:AGTI) to earn \$0.14 per share in the second quarter of 2023.

by Elaine Mendonça — March 12, 2023 in News

